|
|
20 Firstfield Road
Gaithersburg, MD 20878 USA
phone:301-556-4500
fax:301-556-4501
|
|
| Symbol |
IOMI |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.iomai.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Vaccines and immune system stimulants delivered to the skin. |
|
| Management |
| Stanley C Erck, President and CEO; Gregory M. Glenn, M.D., Senior Vice President & Chief Scientific Officer; Kai Chen, Ph.D., Vice President, Business Development; Jin Sook Chung, Vice President, Human Resources; Larry Ellingsworth, Ph.D., Vice President, Research; Sarah A. Frech DVM, MPH, Vice President, Clinical Development; Mervyn L. Hamer, Vice President, Operations; Kimber L. Poffenberger, Ph.D., Vice President, Regulatory Affairs; Robert C. Seid, Vice President, Formulations; Russell P. Wilson, Senior Vice President, Chief Financial Officer and General Counsel |
| |
|
|
|
|
|
|
|
| Keywords |
| drugs, pharmaceuticals, delivery, vaccines, immunology, transdermal, skin, AllergyImmunology, j2008 |
|
|
|
| Description |
|
Iomai Corporation is focused on the discovery, development and commercialization of vaccines and immune system stimulants via transdermal patches. |
|
| Products / Services |
IOMAI currently has four product candidates in development: one to prevent travelers' diarrhea and three targeting influenza and pandemic flu.
|
|
| Technology / Differentiation |
| Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. |
|
|
| Funding |
| Iomai is completing Phase 2 testing of a vaccine for travelers' diarrhea. A Phase 2 field trial found that the needle-free patch vaccine significantly cut the risk of moderate to severe travelers' diarrhea by 75 percent compared with a placebo patch, and the vaccine has been shown in Phase 1 and 2 studies to prompt a strong immune response to the bacteria that is the most common cause of travelers' diarrhea. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members